

# Visible perivascular spaces in elderly patients with dementia

Ramirez, J.<sup>1,2</sup>; Berezuk, C.<sup>1-3</sup>; McNeely, A.A.<sup>1,2</sup>; Scott, C.J.M.<sup>1,2</sup>; Gao, F.Q.<sup>1,2</sup>; & Black, S.E.<sup>1-4</sup>

<sup>1</sup> LC Campbell Cognitive Neurology Research Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto (UofT), Canada; <sup>2</sup> Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Site, Toronto, Canada; <sup>3</sup> Graduate Department of Psychological Clinical Science, UofT Scarborough; <sup>4</sup> Institute of Medical Science, Faculty of Medicine (Neurology), UofT

Sunnybrook  
HEALTH SCIENCES CENTRE

UNIVERSITY OF TORONTO  
FACULTY OF MEDICINE  
Neuroscience Program

HEART & STROKE FOUNDATION  
Canadian Partnership  
for Stroke Recovery

## Background

The brain lacks conventional lymphatic vessels, but recent evidence suggests that the space surrounding the vasculature serves as a proto-lymphatic system to clear interstitial fluid and metabolic waste [1].

Called perivascular (Virchow-Robin) spaces, these tunnels are thought to act as conduits for the clearance of soluble waste and may play an important role in inflammatory and immunological responses in the brain [2].

With age, neurodegeneration, and cerebrovascular disease, these microscopic spaces are quantifiable on conventional MRI [3].

## Objectives

To compare enlarged/visible perivascular space (PVS) volume burden in a sample of normal elderly participants and dementia patients enrolled in the Sunnybrook Dementia Study.


## Discussion

In addition to whole brain atrophy, WMH, and left hippocampal volumes, WM-PVS may be differentially associated with different dementias with varying degrees of cerebral small vessel disease (SVD). The role of SVD and metabolic clearance through the perivascular space, especially in AD, will be explored in future work.

Although previous studies have shown PVS burden to be higher in men in both AD and normal aging [5-7], the potential factors that may explain this sex difference have yet to be fully explored.

These preliminary findings, in the context of recent work on the glymphatic system, provide an exciting new area of research that may be useful in developing novel therapeutic strategies for the treatment of neurovascular and neurodegenerative diseases such as AD and related dementias.


## Results



**Fig. 1** Figure 5 - Mean PVS volumes across different diagnostic groups. Total PVS volumes were significantly different across groups (Kruskal-Wallis,  $p < 0.0001$ ). Post-hoc trend testing showed a significant linear trend across groups ( $p < 0.001$ ), indicating a general linear increase in PVS volumes from NC to VCI (left to right). Bonferroni corrected post-hoc tests showed a significant increase between FTD and DLB ( $p = 0.015$ ) and AD and VCI groups ( $p = 0.0001$ ), suggesting three levels of PVS burden.

Variables	$\beta$ coefficient	$R^2$	P value	95% CI		Sig
				Lower	Upper	
Gender	-.082	-.087	.03	-.510	-.029	n.s.
Education (years)	-.093	-.106	.01	-.072	-.011	**
Disease Severity (DRS total)	-.223	-.207	.00	-.030	-.014	***
BPF	-.138	-.108	.01	-.076	-.013	**
Ventricular CSF	.001	.001	.97	.000	.000	n.s.
Hippocampus Right	-.030	-.021	.59	-.001	.000	n.s.
Hippocampus Left	-.157	-.111	.00	-.001	.000	***
WMH	.123	.095	.02	.000	.000	*
BG-VRS	.027	.025	.52	-.002	.005	n.s.
WM-VRS	.086	.083	.04	.000	.002	*
Lacune	.044	.036	.36	.000	.001	n.s.


**Table 1** Summary of regression results for demographics and imaging measures for small vessel disease and brain atrophy. DRS=dementia rating scale, BPF= brain parenchymal fraction, CSF=cerebrospinal fluid, WMH=white matter hyperintensities, BG-PVS= basal ganglia perivascular space volume, WM-PVS=white matter perivascular space volume.




**Fig. 2** When stratified by disease group, men appeared to have greater PVS volumes compared to women across all diagnostic and normal elderly groups, with the exception of FTD and VCI.

Regression models revealed that education, sex, disease severity (dementia rating scale), WM-PVS, whole brain atrophy (brain parenchymal fraction), left hippocampal volume, and white matter hyperintensities (WMH), significantly accounted for the variance between the dementia groups (Table 1).


## Methods



**Fig. 4** Schematic representation of the brain's perivascular Virchow-Robin space and surrounding tissues. The cortical perivascular space is bounded by the adventitia of the vessel and the astrocyte end-feet, and is filled with CSF from the subarachnoid space. Beta amyloid is thought to accumulate around the blood vessel possibly resulting in perivascular blockage and enlargement of the space, as shown on the right vessel [4].



**Fig. 5.** PVS segmentation overlaid on T1 and T2 in axial and coronal images.



**Fig. 5.** Lesion Explorer (LE). Left image shows LE initial segmentation: gray matter (dark gray) and white matter (light gray), vCSF (yellow), sulcal CSF (blue). Middle image shows WMH segmentation overlaid in red. Right image shows proton density. All images have been skull stripped using the BrainSizer component of LE which includes all sCSF.

### Lesion Explorer (LE)

Basic volumetrics including WMH, lacunes, vCSF, and BPF were obtained from the LE pipeline. PVS volumes were generated using modified LE [5]. Volumetrics were obtained on the following participants sampled from the Sunnybrook Dementia Study:

Normal elderly controls	(NC: n=107)
Mild cognitive impairment	(MCI: n=38)
Frontotemporal dementia	(FTD: n=110)
Dementia with Lewy bodies	(DLB: n=74)
Alzheimer's disease	(AD: n=270)
Vascular cognitive impairment	(VCI: n=89)

### References

- Nedergaard et al. (2013). *Science*.
- Zhang et al. (1990). *J Anat*.
- Wardlaw et al. (2013). *Lancet Neurol*.
- Ramirez et al., (in press). *Cell Mol Neurobiol*.
- Ramirez et al. (2015). *J Alzheimers Dis*.
- Zhu et al. (2010). *Stroke*.
- Zhu et al. (2011). *Am J Neuroradiol*.
- SDS: [www.brainlab.ca/sunnybrookdementiastudy](http://www.brainlab.ca/sunnybrookdementiastudy); ClinicalTrials.gov NCT 01800214

### Acknowledgements

The authors gratefully acknowledge financial support from the Canadian Institutes of Health Research (MOP#13129), the Alzheimer Society of Canada and Alzheimer Association (US), the Heart and Stroke Foundation Canadian Partnership for Stroke Recovery (HSFCPSR), Hurvitz Brain Sciences Research program at Sunnybrook Research Institute, and the Linda C. Campbell Foundation. JR receives partial funding support from the Canadian Vascular Network. JR, CB, AAM, and FQG receive salary support from HSFCPSR and SEB from the Sunnybrook Research Institute, Brill Chair in Neurology Department of Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Department of Medicine (Neurology) Sunnybrook Health Sciences Centre, and the Toronto Dementia Research Alliance.

For more information or to download a copy of this poster, please visit [brainlab.ca/posters](http://brainlab.ca/posters) or scan this QR code

